Literature DB >> 1685924

Short report: plasma somatostatin concentrations in the irritable bowel syndrome.

L J O'Donnell1, K Davidson, D Cameron, J A Wass, M J Farthing.   

Abstract

The description of a patient with the irritable bowel syndrome whose symptoms were completely relieved by the administration of somatostatin raised the possibility that a deficiency of somatostatin may be involved in the pathogenesis of the disorder. We have examined this possibility by studying 11 healthy controls (35 +/- 12 years; mean +/- S.D. 8 female) and 10 irritable bowel syndrome patients (39 +/- 14 years; 7 female) complaining of frequency of defaecation of 4 or more times a day. Plasma somatostatin concentrations were determined by specific radioimmunoassay, fasting and at 15, 30, 45, 60, 90, 120 and 180 min after a standard breakfast. Irritable bowel syndrome patients and controls had similar fasting (27.4 +/- 5.1 vs. 35.2 +/- 4.3 pg/ml; mean +/- S.E.M. and integrated increment of post-prandial (5105 +/- 858 vs. 3885 +/- 793 pg.min/L) plasma concentrations of somatostatin, as assessed by student's t-test. These observations do not support the idea that a state of somatostatin deficiency exists in the irritable bowel syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685924     DOI: 10.1111/j.1365-2036.1991.tb00534.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

1.  Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone.

Authors:  M Bradette; M Delvaux; G Staumont; J Fioramonti; L Bueno; J Frexinos
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

Review 2.  Octreotide in the treatment of refractory diarrhoea and intestinal fistulae.

Authors:  M J Farthing
Journal:  Gut       Date:  1994       Impact factor: 23.059

3.  Frequency and Causes of False-Positive Elevated Plasma Concentrations of Fasting Gut Hormones in a Specialist Neuroendocrine Tumor Center.

Authors:  Olivia L Butler; Monica M Mekhael; Arslan Ahmed; Daniel J Cuthbertson; D Mark Pritchard
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-16       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.